A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
CoronaVac is an inactivated vaccine against SARS-CoV-2 that has been approved by WHO for emergency use. Phase III clinical trials are in progress in several countries, including China, Brazil, Turkey, and Chile, and have shown safety and immunogenicity after two doses of the vaccine.
Article activity feed
-
-
-
SciScore for 10.1101/2021.11.16.21266350: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IACUC: The Institutional Scientific Ethical Committee of Health Sciences reviewed and approved the study protocol at the Pontificia Universidad Católica de Chile (#200708006).
Consent: Informed consent was obtained from all volunteers upon enrollment.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources A standard curve was used to plot the neutralization response in the samples as international units (IU) by using the WHO International Standard for SARS-CoV-2 antibody (NIBSC code 20/136), which was prepared according to the manufacturer’s instructions [17]. SARS-CoV-2suggested: None… SciScore for 10.1101/2021.11.16.21266350: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IACUC: The Institutional Scientific Ethical Committee of Health Sciences reviewed and approved the study protocol at the Pontificia Universidad Católica de Chile (#200708006).
Consent: Informed consent was obtained from all volunteers upon enrollment.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources A standard curve was used to plot the neutralization response in the samples as international units (IU) by using the WHO International Standard for SARS-CoV-2 antibody (NIBSC code 20/136), which was prepared according to the manufacturer’s instructions [17]. SARS-CoV-2suggested: NoneSoftware and Algorithms Sentences Resources All data were analyzed with GraphPad Prism 9.0.1. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04651790 Recruiting Efficacy, Safety, and Immunogenicity of Two Vaccination Sche… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-